White Paper

Degrees of Freedom: The Bright Future of Musculoskeletal Health Care Technology

Data, AI and point-of-care screening devices are revolutionizing the musculoskeletal health care field, giving providers and patients a real-time understanding of recovery and the solutions that can drive success.
By:

White Paper Summary

When the electrocardiogram (ECG) was introduced to heart medicine over 100 years ago, the first commercially available machine, a table model of Einthoven’s electrocardiogram, was 600 pounds and took five people to operate.1 It was scarcely used across the healthcare system. Now ECGs are on every hospital floor and weigh in at only 8 pounds and they are one of the most commonly used tests in modern medicine.

In musculoskeletal health, we are going through the same revolution.

Up until now, objective measures of dynamic joint motion and muscle function have only been available in elite biomotion performance labs with a whopping price tag and large time commitment attached. That powerful musculoskeletal data is now accessible at any point of care, for any injured individual, through the easy to use and even easier to read bioMotion Assessment Platform (bMAP) by FIGUR8.

 

To learn more, visit their website.

FIGUR8, a MIT spin-off company, is the innovation leader in musculoskeletal (MSK) biometrics, redefining the way MSK health is measured to deliver improved clinical and financial outcomes. Our bioMotion Assessment Platform (bMAP) is the first practical solution for measuring MSK function precisely and objectively, at any point of care. This technology enables patients, providers, and payers to have a full picture view regarding joint motion and muscle function during dynamic activities; using movement as a biomarker to improve MSK health. Our powerful, lightweight system combines clinically smart biosensors, intuitive software and artificial intelligence (AI) to improve MSK health — from injury through full recovery.

More from Risk & Insurance